{"id":"6429176f-03be-4086-8a85-e37b033a9715","question":"What should you do if you are breastfeeding and taking ATRIPLA?","reference_answer":"If you are breastfeeding or plan to breastfeed, you should not breastfeed because of the risk of passing HIV-1 to your baby while taking ATRIPLA.","reference_context":"Document 167: ATRIPLA during pregnancy. The purpose of this registry is to collect information\nabout the health of you and your baby. Talk to your healthcare provider about\nhow you can take part in this registry.\nare breastfeeding or plan to breastfeed. ATRIPLA can pass into your breast milk. Do\nnot breastfeed because of the risk of passing HIV-1 to your baby.\nTell your healthcare provider about all the medicines you take\n, including\nprescription and over-the-counter medicines, vitamins and herbal supplements.\nKeep a list of your medicines and show it to your healthcare provider and pharmacist\nwhen you get a new medicine. \nATRIPLA and some medicines may interact with each other causing serious side effects.\nYou can ask your healthcare provider or pharmacist for a list of medicines that interact\nwith ATRIPLA. Do not start a new medicine without telling your healthcare provider. Your\nhealthcare provider can tell you if it is safe to take ATRIPLA with other medicines.\nHow should I take ATRIPLA?","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":167,"topic":"HIV Treatment"}}
{"id":"4094a0a9-f4ac-4a72-9e77-941c62d505b0","question":"How does Emtricitabine interfere with the activity of HIV-1 reverse transcriptase, specifically in relation to the competition with the natural substrate and the incorporation into nascent viral DNA?","reference_answer":"Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.","reference_context":"Document 124: Efavirenz:\n \nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases α, β, γ, and δ are\nnot inhibited by EFV.\nEmtricitabine:\n \nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\nby cellular enzymes to form FTC 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits\nthe activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5'-\ntriphosphate and by being incorporated into nascent viral DNA which results in chain\ntermination. Emtricitabine 5′-triphosphate is a weak inhibitor of mammalian DNA\npolymerases α, β, ε, and mitochondrial DNA polymerase γ.\nTenofovir DF:\n \nTDF is an acyclic nucleoside phosphonate diester analog of adenosine\nmonophosphate. TDF requires initial diester hydrolysis for conversion to tenofovir and\n\nDocument 125: Tenofovir DF:\n \nTDF is an acyclic nucleoside phosphonate diester analog of adenosine\nmonophosphate. TDF requires initial diester hydrolysis for conversion to tenofovir and\nsubsequent phosphorylations by cellular enzymes to form tenofovir diphosphate.\nTenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural\nsubstrate deoxyadenosine 5′-triphosphate and, after incorporation into DNA, by DNA\nchain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA\npolymerases α, β, and mitochondrial DNA polymerase γ.\nAntiviral Activity\nEfavirenz, Emtricitabine, and Tenofovir DF:\n \nIn combination studies evaluating the antiviral\nactivity in cell culture of FTC and EFV together, EFV and tenofovir together, and FTC and\ntenofovir together, additive to synergistic antiviral effects were observed.\nEfavirenz:\n \nThe concentration of EFV inhibiting replication of wild-type laboratory adapted\nstrains and clinical isolates in cell culture by 90–95% (EC","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":124,"topic":"Antiretroviral Pharmacokinetics"}}
{"id":"82a55fb0-eda8-4180-89ae-92696b2f79d2","question":"Are there any contraindications for using ATRIPLA in patients with moderate or severe renal impairment?","reference_answer":"The active ingredients in ATRIPLA are efavirenz, emtricitabine, and tenofovir disoproxil fumarate.","reference_context":"Document 176: Medicines are sometimes prescribed for purposes other than those listed in a Patient\nInformation leaflet. Do not use ATRIPLA for a condition for which it was not prescribed.\nDo not give ATRIPLA to other people, even if they have the same symptoms that you\nhave. It may harm them. You can ask your healthcare provider or pharmacist for\ninformation about ATRIPLA that is written for health professionals.\nWhat are the ingredients of ATRIPLA?\nActive Ingredients:\n efavirenz, emtricitabine, and tenofovir disoproxil fumarate \nInactive Ingredients:\n croscarmellose sodium, hydroxypropyl cellulose, magnesium\nsterate, microcrystalline cellulose, and sodium lauryl sulfate. The film coating contains\npolyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.\nManufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404\nATRIPLA, EMTRIVA, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc., or","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":176,"distracting_context":"disease or other drug therapy.\n8.6 Renal Impairment\nBecause ATRIPLA is a fixed-dose combination, and cannot be dose adjusted, it is not\nrecommended in patients with moderate or severe renal impairment (estimated\ncreatinine clearance below 50 mL\/min) \n[see \nDosage and Administration (2.3)\n, \nWarnings\nand Precautions (5.7)\n].","topic":"HIV Treatment"}}
